*|MC:SUBJECT|*
up-to-date with a click!
Update - Issue January, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Key publications

Other

  1. Djebli N, Martinez JM, Lohan L et al. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28063030
  2. Ou HT, Chang KC, Li CY et al. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062146
  3. Garattini L, Padula A. Cholesterol-lowering drugs: Science and marketing. Journal of the Royal Society of Medicine 2016:141076816681951. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084157
  4. Kheloufi F, Default A, Blin O, Micallef J. Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: The example of comments about statins. Therapie 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28065444
  5. Verdoia M, Pergolini P, Rolla R et al. Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Thrombosis research 2016; 150:90-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=28068529
 

Add on treatments

  1. O'Keefe JH, DiNicolantonio JJ, Lavie CJ. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. Am J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081940
  2. Ferket BS, Hunink MG, Khanji M et al. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077465
  3. Park DB, Jang K, Lee JW et al. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28079517
  4. Al-Kuraishy HM, Al-Gareeb AI. Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile. Journal of basic and clinical pharmacy 2016; 8:8-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28104968
  5. Fei Y, Guyatt GH, Alexander PE et al. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval Clin Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28090731
  6. Gomes GB, Zazula AD, Shigueoka LS et al. A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy. Journal of medicinal food 2017; 20:30-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=28098515
  7. Alkhail BA, Iftikhar R, Shaikh AA. Use of Aspirin and Statin as primary prevention for cardiovascular diseases. Pak J Med Sci 2016; 32:1336-1339. http://www.ncbi.nlm.nih.gov/pubmed/?term=28083021
  8. Rhee MY, Ahn T, Chang K et al. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia. BMC pharmacology & toxicology 2017; 18:2. http://www.ncbi.nlm.nih.gov/pubmed/?term=28057081
  9. Di Pierro F, Putignano P, Ferrara T et al. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia. Clinical pharmacology : advances and applications 2017; 9:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28058034
  10. Hileman CO, Tangpricha V, Sattar A, McComsey GA. Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. J Acquir Immune Defic Syndr 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28045766
 

Adherence

  1. Deshpande S, Quek RG, Forbes CA et al. A systematic review to assess the adherence and persistence with statins. Current medical research and opinion 2017:1-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076703
  2. Vonbank A, Agewall S, Kjeldsen KP et al. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077470
  3. Shalaeva EV, Saner H, Janabaev BB, Shalaeva AV. Tenfold risk increase of major cardiovascular events after high limb amputation with non-compliance for secondary prevention measures. Eur J Prev Cardiol 2017:2047487316687103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28071959

 

Atherosclerosis & Imaging

  1. Kataoka Y, Andrews J, Puri R et al. Plaque burden, microstructures and compositions underachieving very low LDL-C levels. Current opinion in endocrinology, diabetes, and obesity 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28107247
  2. Dai J, Hou J, Xing L et al. Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study. Coronary artery disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28059849
  3. Hileman CO, Tangpricha V, Sattar A, McComsey GA. Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. J Acquir Immune Defic Syndr 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28045766
  4. Schaefer CA, Blatzheim AK, Passon SG et al. Modulation of carotid strain by statin therapy in atherosclerosis patients. VASA. Zeitschrift fur Gefasskrankheiten 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28043217
  5. Yan L, Ye L, Wang K et al. [Atorvastatin improves reflow after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction by decreasing serum uric acid level]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2016; 45:530-535. http://www.ncbi.nlm.nih.gov/pubmed/?term=28087914
 

Atorvastatin/Rosuvastatin

  1. Park JH, Choi BH, Ku SK et al. Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin. Archives of pharmacal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084586
  2. Qiu Y, Wu Y, Meng M et al. Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 87:503-508. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076830
  3. Sadat Pajohanfar N, Mohebbi E, Rad A et al. Protective effects of atorvastatin against morphine-induced tolerance and dependence in mice. Brain Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062186
  4. Oliveira LP, Vieira CP, Marques PP, Pimentel ER. Do different tendons exhibit the same response following chronic exposure to statins? Canadian journal of physiology and pharmacology 2016:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28112540
  5. Nandy A, Gaini S. Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination. Case reports in medicine 2016; 2016:4705492. http://www.ncbi.nlm.nih.gov/pubmed/?term=28115938
  6. Feng X, Gao X, Jia Y et al. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120261
  7. Yim CS, Jeong YS, Lee SY et al. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for an rOATP1B2-Mediated Interaction in Hepatic Transport. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28069721
  8. Sridharan K, Sivaramakrishnan G. Periodic dosing regimens of atorvastatin and rosuvastatin for dyslipidemia: A systematic review and meta-analysis of randomized controlled trials. Eur J Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28063659
  9. Liu W, Zou Z, Jiang H et al. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. Experimental and therapeutic medicine 2017; 13:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=28123475
  10. Blanquiceth Y, Rodriguez-Perea AL, Tabares Guevara JH et al. Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma. Frontiers in immunology 2016; 7:620. http://www.ncbi.nlm.nih.gov/pubmed/?term=28066430
  11. Ou HT, Chang KC, Li CY et al. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062146
  12. Park DB, Jang K, Lee JW et al. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28079517
  13. Byun YS, Yang X, Bao W et al. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol 2017; 69:147-158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081824
  14. Eisen A, Cannon CP, Braunwald E et al. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077384
  15. Al-Kuraishy HM, Al-Gareeb AI. Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile. Journal of basic and clinical pharmacy 2016; 8:8-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28104968
  16. Talwar N, Musch DC, Stein JD. Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma. JAMA ophthalmology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28114645
  17. Troyanov Y, Landon-Cardinal O, Fritzler MJ et al. Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype. Medicine (Baltimore) 2017; 96:e5694. http://www.ncbi.nlm.nih.gov/pubmed/?term=28099331
  18. Beg S, Jain S, Kushwah V et al. Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a Quality by Design-driven perspective. Nanomedicine (Lond) 2017; 12:333-356. http://www.ncbi.nlm.nih.gov/pubmed/?term=28093941
  19. He Y, Huang H, Farischon C et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncology reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28075470
  20. Jia YC, Xu J, Chen HH et al. The Effect of Atorvastatin on the Viability of Ischemic Skin Flaps in Diabetic Rats. Plastic and reconstructive surgery 2017; 139:425e-433e. http://www.ncbi.nlm.nih.gov/pubmed/?term=28121873
  21. Zaid AN, Al Ramahi R, Cortesi R et al. Investigation of the Bioequivalence of Rosuvastatin 20 mg Tablets after a Single Oral Administration in Mediterranean Arabs Using a Validated LC-MS/MS Method. Scientia pharmaceutica 2016; 84:536-546. http://www.ncbi.nlm.nih.gov/pubmed/?term=28117319
  22. Rodriguez S, Raurell I, Torres-Arauz M et al. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Scientific reports 2017; 7:40461. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084470
  23. Kheloufi F, Default A, Blin O, Micallef J. Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: The example of comments about statins. Therapie 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28065444
  24. Yan L, Ye L, Wang K et al. [Atorvastatin improves reflow after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction by decreasing serum uric acid level]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2016; 45:530-535. http://www.ncbi.nlm.nih.gov/pubmed/?term=28087914
 

Basic science

  1. Medeiros VF, Azevedo IM, Carvalho MD et al. Effects of cococonut water and simvastatin in the treatment of sepsis and hemorrhagic shock in rats. Acta Cir Bras 2016; 31:826-833. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076507
  2. Ferretti G, Bacchetti T, Banach M et al. Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations. Angiology 2016:3319716688301. http://www.ncbi.nlm.nih.gov/pubmed/?term=28068800
  3. Qiu Y, Wu Y, Meng M et al. Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 87:503-508. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076830
  4. Oikonomidis N, Kavantzas N, Korou LM et al. Pre-treatment with simvastatin prevents the induction of diet-induced atherosclerosis in a rabbit model. Biomedical reports 2016; 5:667-674. http://www.ncbi.nlm.nih.gov/pubmed/?term=28101339
  5. Sadat Pajohanfar N, Mohebbi E, Rad A et al. Protective effects of atorvastatin against morphine-induced tolerance and dependence in mice. Brain Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062186
  6. Oliveira LP, Vieira CP, Marques PP, Pimentel ER. Do different tendons exhibit the same response following chronic exposure to statins? Canadian journal of physiology and pharmacology 2016:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28112540
  7. Yim CS, Jeong YS, Lee SY et al. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for an rOATP1B2-Mediated Interaction in Hepatic Transport. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28069721
  8. Long T, Tang T, Hao Y et al. Effect of simvastatin on osteogenesis of the lumbar vertebrae in ovariectomized rats. Experimental and therapeutic medicine 2016; 12:3951-3957. http://www.ncbi.nlm.nih.gov/pubmed/?term=28105128
  9. Blanquiceth Y, Rodriguez-Perea AL, Tabares Guevara JH et al. Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma. Frontiers in immunology 2016; 7:620. http://www.ncbi.nlm.nih.gov/pubmed/?term=28066430
  10. Arpornmaeklong P, Pripatnanont P, Chookiatsiri C, Tangtrakulwanich B. Effects of Titanium Surface Microtopography and Simvastatin on Growth and Osteogenic Differentiation of Human Mesenchymal Stem Cells in Estrogen-Deprived Cell Culture. The International journal of oral & maxillofacial implants 2017; 32:e35-e46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28095523
  11. Tun T, Kang YS. Effects of simvastatin on CAT-1-mediated arginine transport and NO level under high glucose conditions in conditionally immortalized rat inner blood-retinal barrier cell lines (TR-iBRB). Microvascular research 2017; 111:60-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=28089735
  12. Beg S, Jain S, Kushwah V et al. Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a Quality by Design-driven perspective. Nanomedicine (Lond) 2017; 12:333-356. http://www.ncbi.nlm.nih.gov/pubmed/?term=28093941
  13. He Y, Huang H, Farischon C et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncology reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28075470
  14. Jia YC, Xu J, Chen HH et al. The Effect of Atorvastatin on the Viability of Ischemic Skin Flaps in Diabetic Rats. Plastic and reconstructive surgery 2017; 139:425e-433e. http://www.ncbi.nlm.nih.gov/pubmed/?term=28121873
  15. Rodriguez S, Raurell I, Torres-Arauz M et al. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Scientific reports 2017; 7:40461. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084470
  16. Chen Q, Shi X, Tan Q et al. Simvastatin Promotes Hematoma Absorption and Reduces Hydrocephalus Following Intraventricular Hemorrhage in Part by Upregulating CD36. Translational stroke research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28102508
  17. Nicoletti P, Aithal GP, Bjornsson ES et al. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28043905
  18. Goodarzi Z, Karami E, Ahmadizadeh M. Simvastatin attenuates chromium-induced nephrotoxicity in rats. J Nephropathol 2017; 6:5-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28042547
  19. Wang F, Ma H, Liang WJ et al. Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28061433
 

Cancer

  1. Beg MS, Gupta A, Sher D et al. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. American journal of clinical oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28079594
  2. Lee Y, Lee KH, Lee GK et al. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Non-Adenocarcinomatous Non-Small Cell Lung Cancer. Cancer research and treatment : official journal of Korean Cancer Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28111428
  3. May MB, Glode A. Novel Uses for Lipid-Lowering Agents. Journal of the advanced practitioner in oncology 2016; 7:181-187. http://www.ncbi.nlm.nih.gov/pubmed/?term=28090367
  4. Huang BZ, Chang JI, Li E et al. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. Journal of the National Cancer Institute 2017; 109. http://www.ncbi.nlm.nih.gov/pubmed/?term=28040693
  5. He Y, Huang H, Farischon C et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncology reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28075470
  6. Smith A, Murphy L, Bennett K, Barron TI. Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28101676

 

Cost-effectiveness

  1. Ferket BS, Hunink MG, Khanji M et al. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077465
  2. Toth PP, Danese M, Villa G et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. Journal of medical economics 2017:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28097904
  3. Arrieta A, Page TF, Veledar E, Nasir K. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. PLoS One 2017; 12:e0169761. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081164
     

CVD

  1. Rousan TA, Mathew ST, Thadani U. Drug Therapy for Stable Angina Pectoris. Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120185
  2. Liu W, Zou Z, Jiang H et al. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. Experimental and therapeutic medicine 2017; 13:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=28123475
  3. Eisen A, Cannon CP, Braunwald E et al. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077384
  4. Calcagno S, Stio RE, Mancone M et al. The statin therapy to prevent atrial fibrillation after cardiac surgery: Shakespearean dilemma. J Thorac Dis 2016; 8:2986-2990. http://www.ncbi.nlm.nih.gov/pubmed/?term=28066564
  5. Zhang W, Ji F, Yu X, Wang X. Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. Medicine (Baltimore) 2017; 96:e5469. http://www.ncbi.nlm.nih.gov/pubmed/?term=28072688
  6. Yan L, Ye L, Wang K et al. [Atorvastatin improves reflow after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction by decreasing serum uric acid level]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2016; 45:530-535. http://www.ncbi.nlm.nih.gov/pubmed/?term=28087914
  7. Wu PS. [Clinical considerations of statin therapy for hypertensive patients]. Zhonghua xin xue guan bing za zhi 2017; 45:3-4. http://www.ncbi.nlm.nih.gov/pubmed/?term=28100338
 

FH

  1. Lee SH. Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics. Endocrinol Metab (Seoul) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28116871
 

Guidelines

  1. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement. American family physician 2017; 95:Online. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084711
  2. Last AR, Ference JD, Menzel ER. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults. American family physician 2017; 95:78-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084704
  3. Wadia SK, Belkin M, Chow KS et al. In-hospital statin underutilization among high-risk patients: delayed uptake of the 2013 cholesterol guidelines in a U.S. cohort. Hospital practice (1995) 2017; 45:16-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28092990
  4. Falk E, Mortensen MB. Statin Eligibility Under American and European Cholesterol Guidelines. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28097366
  5. Lee JC, Zdrojewski T, Navar AM. Statin Eligibility Under American and European Cholesterol Guidelines-Reply. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28097333
  6. Tunney RK, Jr., Johnson DC, Wang L, Cox ZL. Impact of Pharmacist Intervention to Increase Compliance With Guideline-Directed Statin Therapy During an Acute Coronary Syndrome Hospitalization. The Annals of pharmacotherapy 2017:1060028016687322. http://www.ncbi.nlm.nih.gov/pubmed/?term=28058865
 

Inflammation

  1. Feng X, Gao X, Jia Y et al. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120261
  2. Blanquiceth Y, Rodriguez-Perea AL, Tabares Guevara JH et al. Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma. Frontiers in immunology 2016; 7:620. http://www.ncbi.nlm.nih.gov/pubmed/?term=28066430

 

LDL- related parameters

  1. Tournadre A, Pereira B, Dubost JJ et al. Management of dyslipidemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. Clinical and experimental rheumatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28079508
  2. Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clinical research in cardiology : official journal of the German Cardiac Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28124099
  3. Byun YS, Yang X, Bao W et al. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol 2017; 69:147-158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081824
  4. Feske SK. A New Treatable Risk Factor for Stroke and Atherosclerotic Cardiovascular Disease? J Am Coll Cardiol 2017; 69:159-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081825
  5. Zhang W, Ji F, Yu X, Wang X. Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. Medicine (Baltimore) 2017; 96:e5469. http://www.ncbi.nlm.nih.gov/pubmed/?term=28072688
  6. Wang S, Cai R, Yuan Y et al. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Scientific reports 2017; 7:39982. http://www.ncbi.nlm.nih.gov/pubmed/?term=28071756
 

Meta-analyses

  1. Ferretti G, Bacchetti T, Banach M et al. Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations. Angiology 2016:3319716688301. http://www.ncbi.nlm.nih.gov/pubmed/?term=28068800
  2. Deshpande S, Quek RG, Forbes CA et al. A systematic review to assess the adherence and persistence with statins. Current medical research and opinion 2017:1-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076703
  3. Sridharan K, Sivaramakrishnan G. Periodic dosing regimens of atorvastatin and rosuvastatin for dyslipidemia: A systematic review and meta-analysis of randomized controlled trials. Eur J Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28063659
  4. Garattini L, Padula A. Cholesterol-lowering drugs: Science and marketing. Journal of the Royal Society of Medicine 2016:141076816681951. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084157
  5. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. The Lancet. Haematology 2017; 4:e83-e93. http://www.ncbi.nlm.nih.gov/pubmed/?term=28089655
  6. Wang S, Cai R, Yuan Y et al. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Scientific reports 2017; 7:39982. http://www.ncbi.nlm.nih.gov/pubmed/?term=28071756

 

Metabolic Syndrome - Diabetes

  1. Chung YR, Park SW, Choi SY et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovascular diabetology 2017; 16:4. http://www.ncbi.nlm.nih.gov/pubmed/?term=28061854
  2. Feng X, Gao X, Jia Y et al. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120261
  3. Lin MJ, Chen CY, Lin HD, Wu HP. Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. BMC Cardiovasc Disord 2017; 17:12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28056847
  4. Weerarathna TP, Herath HM, Liyanage G. Prevalence of low HDL cholesterol and its associations among Sri Lankan patients with diabetes mellitus on statin therapy. Diabetes & metabolic syndrome 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28057504
 

New Treatments

  1. O'Keefe JH, DiNicolantonio JJ, Lavie CJ. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. Am J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081940
  2. Lee SH. Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics. Endocrinol Metab (Seoul) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28116871
  3. Vogt A. [PCSK9 inhibitors : Current clinical relevance]. Internist (Berl) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28083599
  4. Toth PP, Danese M, Villa G et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. Journal of medical economics 2017:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28097904
  5. Garattini L, Padula A. Cholesterol-lowering drugs: Science and marketing. Journal of the Royal Society of Medicine 2016:141076816681951. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084157
  6. Desai NR, Giugliano RP, Wasserman SM et al. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28122070
  7. Shah P, Glueck CJ, Goldenberg N et al. Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. Lipids Health Dis 2017; 16:19. http://www.ncbi.nlm.nih.gov/pubmed/?term=28115017
  8. Arrieta A, Page TF, Veledar E, Nasir K. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. PLoS One 2017; 12:e0169761. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081164
  9. Rodriguez S, Raurell I, Torres-Arauz M et al. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Scientific reports 2017; 7:40461. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084470
  10. Whayne TF, Jr. PCSK9 inhibitors in the current management of atherosclerosis. Archivos de cardiologia de Mexico 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28038950
  11. Ferri N, Corsini A, Sirtori CR, Ruscica M. Bococizumab for the treatment of hypercholesterolaemia. Expert opinion on biological therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28060539
 

Peripheral Artery Disease

  1. Shalaeva EV, Saner H, Janabaev BB, Shalaeva AV. Tenfold risk increase of major cardiovascular events after high limb amputation with non-compliance for secondary prevention measures. Eur J Prev Cardiol 2017:2047487316687103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28071959
 

Pleiotropic effects of statins

  1. Medeiros VF, Azevedo IM, Carvalho MD et al. Effects of cococonut water and simvastatin in the treatment of sepsis and hemorrhagic shock in rats. Acta Cir Bras 2016; 31:826-833. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076507
  2. Galyfos G, Sianou A, Filis K. Pleiotropic effects of statins in the perioperative setting. Annals of cardiac anaesthesia 2017; 20:S43-s48. http://www.ncbi.nlm.nih.gov/pubmed/?term=28074822
  3. Caffrey AR, Timbrook TT, Noh E et al. Evidence to support continuation of statin therapy in patients with Staphylococcus aureus bacteremia. Antimicrobial agents and chemotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28069650
  4. Qiu Y, Wu Y, Meng M et al. Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 87:503-508. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076830
  5. Sadat Pajohanfar N, Mohebbi E, Rad A et al. Protective effects of atorvastatin against morphine-induced tolerance and dependence in mice. Brain Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062186
  6. Chung YR, Park SW, Choi SY et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovascular diabetology 2017; 16:4. http://www.ncbi.nlm.nih.gov/pubmed/?term=28061854
  7. Sodi R, Eastwood J, Caslake M et al. Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clinica chimica acta; international journal of clinical chemistry 2017; 466:13-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062296
  8. Feng X, Gao X, Jia Y et al. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120261
  9. Long T, Tang T, Hao Y et al. Effect of simvastatin on osteogenesis of the lumbar vertebrae in ovariectomized rats. Experimental and therapeutic medicine 2016; 12:3951-3957. http://www.ncbi.nlm.nih.gov/pubmed/?term=28105128
  10. Arpornmaeklong P, Pripatnanont P, Chookiatsiri C, Tangtrakulwanich B. Effects of Titanium Surface Microtopography and Simvastatin on Growth and Osteogenic Differentiation of Human Mesenchymal Stem Cells in Estrogen-Deprived Cell Culture. The International journal of oral & maxillofacial implants 2017; 32:e35-e46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28095523
  11. McCann P, Hogg RE, Azuara-Blanco A. Author Response: Statin Use and Open-Angle Glaucoma: Evidence From Observational Studies. Investigative ophthalmology & visual science 2017; 58:158-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=28114574
  12. Ng JC, Fung MM, Chan HH, Lai JS. Statin Use and Open-Angle Glaucoma: Evidence From Observational Studies. Investigative ophthalmology & visual science 2017; 58:155-157. http://www.ncbi.nlm.nih.gov/pubmed/?term=28114573
  13. Talwar N, Musch DC, Stein JD. Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma. JAMA ophthalmology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28114645
  14. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. The Lancet. Haematology 2017; 4:e83-e93. http://www.ncbi.nlm.nih.gov/pubmed/?term=28089655
  15. Zheng P, Wu QL, Li BB et al. Simvastatin ameliorates graft-vs-host disease by regulating angiopoietin-1 and angiopoietin-2 in a murine model. Leukemia research 2017; 55:49-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=28122283
  16. Alkhail BA, Iftikhar R, Shaikh AA. Use of Aspirin and Statin as primary prevention for cardiovascular diseases. Pak J Med Sci 2016; 32:1336-1339. http://www.ncbi.nlm.nih.gov/pubmed/?term=28083021
  17. Rodriguez S, Raurell I, Torres-Arauz M et al. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Scientific reports 2017; 7:40461. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084470
  18. Verdoia M, Pergolini P, Rolla R et al. Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Thrombosis research 2016; 150:90-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=28068529
  19. Gong J, Sun H, Yang Z et al. Effect of Simvastatin and Relationship between Bilirubin and Blood Lipid Level in Patients with Glucocorticoid-resistant Nephrotic Syndrome. The West Indian medical journal 2015. http://www.ncbi.nlm.nih.gov/pubmed/?term=28103332
  20. Alffenaar JC, Akkerman OW, van Hest R. Statin Adjunctive Therapy for Tuberculosis Treatment. Antimicrobial agents and chemotherapy 2016; 60:7004. http://www.ncbi.nlm.nih.gov/pubmed/?term=28045667
  21. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation research 2017; 120:229-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=28057795
  22. Raposio E, Libondi G, Bertozzi N et al. Effects of Topic Simvastatin for the Treatment of Chronic Vascular Cutaneous Ulcers: A Pilot Study. The journal of the American College of Clinical Wound Specialists 2015; 7:13-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28053863
  23. Goodarzi Z, Karami E, Ahmadizadeh M. Simvastatin attenuates chromium-induced nephrotoxicity in rats. J Nephropathol 2017; 6:5-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28042547

 

Primary Prevention

  1. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement. American family physician 2017; 95:Online. http://www.ncbi.nlm.nih.gov/pubmed/?term=28084711
  2. Yang Q, Zhong Y, Gillespie C et al. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study. BMJ Open 2017; 7:e011684. http://www.ncbi.nlm.nih.gov/pubmed/?term=28119384
  3. Bosomworth NJ. Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia. Journal of the American Board of Family Medicine : JABFM 2016; 29:727-740. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076256
 

Registry data

  1. Spagnuolo V, Galli L, Poli A et al. Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC infectious diseases 2017; 17:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=28061820
  2. Chung YR, Park SW, Choi SY et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovascular diabetology 2017; 16:4. http://www.ncbi.nlm.nih.gov/pubmed/?term=28061854
  3. Tournadre A, Pereira B, Dubost JJ et al. Management of dyslipidemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. Clinical and experimental rheumatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28079508
  4. Feng X, Gao X, Jia Y et al. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120261
  5. Ou HT, Chang KC, Li CY et al. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011. Int J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062146
  6. Zhang W, Ji F, Yu X, Wang X. Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. Medicine (Baltimore) 2017; 96:e5469. http://www.ncbi.nlm.nih.gov/pubmed/?term=28072688
  7. Alkhail BA, Iftikhar R, Shaikh AA. Use of Aspirin and Statin as primary prevention for cardiovascular diseases. Pak J Med Sci 2016; 32:1336-1339. http://www.ncbi.nlm.nih.gov/pubmed/?term=28083021
  8. May HT, Bair TL, Reiss-Brennan B et al. The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. Psychology, health & medicine 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28111972
  9. Di Pierro F, Putignano P, Ferrara T et al. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia. Clinical pharmacology : advances and applications 2017; 9:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28058034
  10. Huang BZ, Chang JI, Li E et al. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. Journal of the National Cancer Institute 2017; 109. http://www.ncbi.nlm.nih.gov/pubmed/?term=28040693
  11. Al-Kindi SG, DeCicco A, Longenecker CT et al. Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28052161
 

Renal Disease

  1. Dimmitt SB, Martin JH. Lipid and other management to improve arterial disease and survival in end stage renal disease. Expert Opin Pharmacother 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28110562
  2. Cho EY, Myoung C, Park HS et al. Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease. PLoS One 2017; 12:e0170017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081262
 

Reviews

  1. O'Keefe JH, DiNicolantonio JJ, Lavie CJ. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. Am J Cardiol 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081940
  2. Galyfos G, Sianou A, Filis K. Pleiotropic effects of statins in the perioperative setting. Annals of cardiac anaesthesia 2017; 20:S43-s48. http://www.ncbi.nlm.nih.gov/pubmed/?term=28074822
  3. Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clinical research in cardiology : official journal of the German Cardiac Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28124099
  4. Deshpande S, Quek RG, Forbes CA et al. A systematic review to assess the adherence and persistence with statins. Current medical research and opinion 2017:1-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076703
  5. Kataoka Y, Andrews J, Puri R et al. Plaque burden, microstructures and compositions underachieving very low LDL-C levels. Current opinion in endocrinology, diabetes, and obesity 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28107247
  6. Rousan TA, Mathew ST, Thadani U. Drug Therapy for Stable Angina Pectoris. Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120185
  7. Lee SH. Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics. Endocrinol Metab (Seoul) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28116871
  8. Vonbank A, Agewall S, Kjeldsen KP et al. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077470
  9. Dimmitt SB, Martin JH. Lipid and other management to improve arterial disease and survival in end stage renal disease. Expert Opin Pharmacother 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28110562
  10. Vogt A. [PCSK9 inhibitors : Current clinical relevance]. Internist (Berl) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28083599
  11. May MB, Glode A. Novel Uses for Lipid-Lowering Agents. Journal of the advanced practitioner in oncology 2016; 7:181-187. http://www.ncbi.nlm.nih.gov/pubmed/?term=28090367
  12. Bosomworth NJ. Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia. Journal of the American Board of Family Medicine : JABFM 2016; 29:727-740. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076256
  13. Fei Y, Guyatt GH, Alexander PE et al. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval Clin Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28090731
  14. Calcagno S, Stio RE, Mancone M et al. The statin therapy to prevent atrial fibrillation after cardiac surgery: Shakespearean dilemma. J Thorac Dis 2016; 8:2986-2990. http://www.ncbi.nlm.nih.gov/pubmed/?term=28066564
  15. Cho EY, Myoung C, Park HS et al. Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease. PLoS One 2017; 12:e0170017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081262
  16. Shagroni T, Park C, Rouah E, Whiteru O. Statin-associated autoimmune myopathy. Rheumatology (Oxford) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28115598
  17. Tonstad S. [Statin intolerance]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2017; 137:36-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28073228
  18. Whayne TF, Jr. PCSK9 inhibitors in the current management of atherosclerosis. Archivos de cardiologia de Mexico 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28038950
  19. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation research 2017; 120:229-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=28057795
  20. Ghosal S, Sinha B. Secondary cvd prevention-Lipid modification strategies: A critical analysis. Diabetes & metabolic syndrome 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28041920

 

Safety and side effects

  1. Spagnuolo V, Galli L, Poli A et al. Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC infectious diseases 2017; 17:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=28061820
  2. Mazzanti G, Moro PA, Raschi E et al. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28093797
  3. Oliveira LP, Vieira CP, Marques PP, Pimentel ER. Do different tendons exhibit the same response following chronic exposure to statins? Canadian journal of physiology and pharmacology 2016:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28112540
  4. Nandy A, Gaini S. Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination. Case reports in medicine 2016; 2016:4705492. http://www.ncbi.nlm.nih.gov/pubmed/?term=28115938
  5. Taha DA, Zgair A, Lee JB et al. Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity. Eur J Pharm Sci 2017; 100:163-175. http://www.ncbi.nlm.nih.gov/pubmed/?term=28104473
  6. Bosomworth NJ. Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia. Journal of the American Board of Family Medicine : JABFM 2016; 29:727-740. http://www.ncbi.nlm.nih.gov/pubmed/?term=28076256
  7. Lin W, Ji T, Einolf H et al. Evaluation of drug-drug interaction potential between sacubitril/valsartan (LCZ696) and statins using a physiologically-based pharmacokinetic model. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28089685
  8. Drug interaction: dabigatran (Pradaxa) and statins. The Medical letter on drugs and therapeutics 2017; 59:26. http://www.ncbi.nlm.nih.gov/pubmed/?term=28118653
  9. Troyanov Y, Landon-Cardinal O, Fritzler MJ et al. Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype. Medicine (Baltimore) 2017; 96:e5694. http://www.ncbi.nlm.nih.gov/pubmed/?term=28099331
  10. Shagroni T, Park C, Rouah E, Whiteru O. Statin-associated autoimmune myopathy. Rheumatology (Oxford) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28115598
  11. Tiniakou E, Pinal-Fernandez I, Lloyd TE et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28096458
  12. Wang S, Cai R, Yuan Y et al. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Scientific reports 2017; 7:39982. http://www.ncbi.nlm.nih.gov/pubmed/?term=28071756
  13. Kheloufi F, Default A, Blin O, Micallef J. Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: The example of comments about statins. Therapie 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28065444
  14. Tonstad S. [Statin intolerance]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2017; 137:36-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28073228
  15. Thompson PD. MY APPROACH to Managing Statin-Associated Muscle Symptoms. Trends Cardiovasc Med 2017; 27:160-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=28107840
  16. Watson KE, Sallam T. MY APPROACH to the Patient With Memory Loss Who Needs a Statin. Trends Cardiovasc Med 2017; 27:158-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=28107839
  17. Calza L, Magistrelli E, Colangeli V et al. Significant association between statin-associated myalgia and vitamin d deficiency among treated hiv-infected patients. Aids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28060020
  18. Steffen C. [Red yeast rice: An unsafe food supplement?]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28054118
  19. Nicoletti P, Aithal GP, Bjornsson ES et al. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28043905
  20. Mgahsoodi N, Crook MA. A case of charcot-marie-Tooth (CMT) disease with hypercholesterolaemia and statin side-effects: A case report and literature review. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28038830
  21. Frydrychowicz C, Pasieka B, Pierer M et al. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. Journal of medical case reports 2017; 11:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28049514

 

Stroke and CNS

  1. Byun YS, Yang X, Bao W et al. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol 2017; 69:147-158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081824
  2. Feske SK. A New Treatable Risk Factor for Stroke and Atherosclerotic Cardiovascular Disease? J Am Coll Cardiol 2017; 69:159-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081825
 

Triglycerides HDL-C and Non HDL-C

  1. Joshi PH, Miller PE, Martin SS et al. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared to pravastatin in HIV-infected patients: The INTREPID trial. Aids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28121706
  2. Weerarathna TP, Herath HM, Liyanage G. Prevalence of low HDL cholesterol and its associations among Sri Lankan patients with diabetes mellitus on statin therapy. Diabetes & metabolic syndrome 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28057504
 

Trials

  1. Joshi PH, Miller PE, Martin SS et al. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared to pravastatin in HIV-infected patients: The INTREPID trial. Aids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28121706
  2. Caffrey AR, Timbrook TT, Noh E et al. Evidence to support continuation of statin therapy in patients with Staphylococcus aureus bacteremia. Antimicrobial agents and chemotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28069650
  3. Sodi R, Eastwood J, Caslake M et al. Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clinica chimica acta; international journal of clinical chemistry 2017; 466:13-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=28062296
  4. Feng X, Gao X, Jia Y et al. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28120261
  5. Shalaeva EV, Saner H, Janabaev BB, Shalaeva AV. Tenfold risk increase of major cardiovascular events after high limb amputation with non-compliance for secondary prevention measures. Eur J Prev Cardiol 2017:2047487316687103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28071959
  6. Liu W, Zou Z, Jiang H et al. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. Experimental and therapeutic medicine 2017; 13:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=28123475
  7. Ferket BS, Hunink MG, Khanji M et al. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077465
  8. Park DB, Jang K, Lee JW et al. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28079517
  9. Byun YS, Yang X, Bao W et al. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol 2017; 69:147-158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081824
  10. Feske SK. A New Treatable Risk Factor for Stroke and Atherosclerotic Cardiovascular Disease? J Am Coll Cardiol 2017; 69:159-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=28081825
  11. Eisen A, Cannon CP, Braunwald E et al. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28077384
  12. Al-Kuraishy HM, Al-Gareeb AI. Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile. Journal of basic and clinical pharmacy 2016; 8:8-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28104968
  13. Gomes GB, Zazula AD, Shigueoka LS et al. A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy. Journal of medicinal food 2017; 20:30-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=28098515
  14. Tiniakou E, Pinal-Fernandez I, Lloyd TE et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28096458
  15. Zaid AN, Al Ramahi R, Cortesi R et al. Investigation of the Bioequivalence of Rosuvastatin 20 mg Tablets after a Single Oral Administration in Mediterranean Arabs Using a Validated LC-MS/MS Method. Scientia pharmaceutica 2016; 84:536-546. http://www.ncbi.nlm.nih.gov/pubmed/?term=28117319
  16. Verdoia M, Pergolini P, Rolla R et al. Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Thrombosis research 2016; 150:90-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=28068529
  17. Gong J, Sun H, Yang Z et al. Effect of Simvastatin and Relationship between Bilirubin and Blood Lipid Level in Patients with Glucocorticoid-resistant Nephrotic Syndrome. The West Indian medical journal 2015. http://www.ncbi.nlm.nih.gov/pubmed/?term=28103332
  18. Yan L, Ye L, Wang K et al. [Atorvastatin improves reflow after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction by decreasing serum uric acid level]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2016; 45:530-535. http://www.ncbi.nlm.nih.gov/pubmed/?term=28087914
  19. Calza L, Magistrelli E, Colangeli V et al. Significant association between statin-associated myalgia and vitamin d deficiency among treated hiv-infected patients. Aids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28060020
  20. Lin MJ, Chen CY, Lin HD, Wu HP. Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. BMC Cardiovasc Disord 2017; 17:12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28056847
  21. Rhee MY, Ahn T, Chang K et al. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia. BMC pharmacology & toxicology 2017; 18:2. http://www.ncbi.nlm.nih.gov/pubmed/?term=28057081
  22. Dai J, Hou J, Xing L et al. Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study. Coronary artery disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28059849
  23. Hileman CO, Tangpricha V, Sattar A, McComsey GA. Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. J Acquir Immune Defic Syndr 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28045766
  24. Raposio E, Libondi G, Bertozzi N et al. Effects of Topic Simvastatin for the Treatment of Chronic Vascular Cutaneous Ulcers: A Pilot Study. The journal of the American College of Clinical Wound Specialists 2015; 7:13-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28053863
  25. Schaefer CA, Blatzheim AK, Passon SG et al. Modulation of carotid strain by statin therapy in atherosclerosis patients. VASA. Zeitschrift fur Gefasskrankheiten 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28043217
 

Women and elderly

  1. Dai J, Hou J, Xing L et al. Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study. Coronary artery disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=2805984

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.

Cancella iscrizione | Unsubscribe | Inviato con MailUp